410 related articles for article (PubMed ID: 29775092)
1. A prospective, multi-centre US clinical trial to determine accuracy of FebriDx point-of-care testing for acute upper respiratory infections with and without a confirmed fever.
Shapiro NI; Self WH; Rosen J; Sharp SC; Filbin MR; Hou PC; Parekh AD; Kurz MC; Sambursky R
Ann Med; 2018 Aug; 50(5):420-429. PubMed ID: 29775092
[TBL] [Abstract][Full Text] [Related]
2. FebriDx
Shirley M
Mol Diagn Ther; 2019 Dec; 23(6):803-809. PubMed ID: 31691924
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic Accuracy of FebriDx: A Rapid Test to Detect Immune Responses to Viral and Bacterial Upper Respiratory Infections.
Self WH; Rosen J; Sharp SC; Filbin MR; Hou PC; Parekh AD; Kurz MC; Shapiro NI
J Clin Med; 2017 Oct; 6(10):. PubMed ID: 28991170
[TBL] [Abstract][Full Text] [Related]
4. Utility of the FebriDx point-of-care test for rapid triage and identification of possible coronavirus disease 2019 (COVID-19).
Karim N; Ashraf MZ; Naeem M; Anwar T; Aung H; Mallik S; Avraam E; Kiran S; Bandapaati S; Khan F; Tsaknis G; Reddy R
Int J Clin Pract; 2021 Mar; 75(3):e13702. PubMed ID: 32896946
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of C-reactive protein and myxovirus resistance protein A to guide the rational use of antibiotics among acute febrile adult patients in Northwest Ethiopia.
Akelew Y; Derbew A; Lemma M; Negash M; Bewket G; Belay G; Pollmann J; Adriaensen W; Adane A; Mohammed R; van Griensven J; Cnops L
Int J Infect Dis; 2020 Dec; 101():276-282. PubMed ID: 33002622
[TBL] [Abstract][Full Text] [Related]
6. Use of the FebriDx® host-response point-of-care test may reduce antibiotic use for respiratory tract infections in primary care: a mixed-methods feasibility study.
Wilcox CR; Odeh N; Clark TW; Muller I; Becque T; Todd A; Islam N; Little P; Davies F; McGavin J; Francis N
J Antimicrob Chemother; 2024 Jun; 79(6):1441-1449. PubMed ID: 38708643
[TBL] [Abstract][Full Text] [Related]
7. Emergency Department point-of-care antiviral host response testing is accurate during periods of multiple respiratory virus co-circulation.
Brendish NJ; Davis C; Chapman ME; Borca F; Waddington D; Hill C; White N; Clark TW
J Infect; 2024 Jan; 88(1):41-47. PubMed ID: 37977337
[TBL] [Abstract][Full Text] [Related]
8. Diagnosis of viral infections using myxovirus resistance protein A (MxA).
Engelmann I; Dubos F; Lobert PE; Houssin C; Degas V; Sardet A; Decoster A; Dewilde A; Martinot A; Hober D
Pediatrics; 2015 Apr; 135(4):e985-93. PubMed ID: 25802344
[TBL] [Abstract][Full Text] [Related]
9. A host-protein signature is superior to other biomarkers for differentiating between bacterial and viral disease in patients with respiratory infection and fever without source: a prospective observational study.
Ashkenazi-Hoffnung L; Oved K; Navon R; Friedman T; Boico O; Paz M; Kronenfeld G; Etshtein L; Cohen A; Gottlieb TM; Eden E; Chistyakov I; Srugo I; Klein A; Ashkenazi S; Scheuerman O
Eur J Clin Microbiol Infect Dis; 2018 Jul; 37(7):1361-1371. PubMed ID: 29700762
[TBL] [Abstract][Full Text] [Related]
10. Performance of the FebriDx Rapid Point-of-Care Test for Differentiating Bacterial and Viral Respiratory Tract Infections in Patients with a Suspected Respiratory Tract Infection in the Emergency Department.
Tong-Minh K; Daenen K; Endeman H; Ramakers C; Gommers D; van Gorp E; van der Does Y
J Clin Med; 2023 Dec; 13(1):. PubMed ID: 38202172
[TBL] [Abstract][Full Text] [Related]
11. Observational multi-centre, prospective study to characterize novel pathogen-and host-related factors in hospitalized patients with lower respiratory tract infections and/or sepsis - the "TAILORED-Treatment" study.
van Houten CB; Oved K; Eden E; Cohen A; Engelhard D; Boers S; Kraaij R; Karlsson R; Fernandez D; Gonzalez E; Li Y; Stubbs A; Moore ERB; Hays JP; Bont LJ
BMC Infect Dis; 2018 Aug; 18(1):377. PubMed ID: 30086729
[TBL] [Abstract][Full Text] [Related]
12. Performance of C-reactive protein and procalcitonin to distinguish viral from bacterial and malarial causes of fever in Southeast Asia.
Lubell Y; Blacksell SD; Dunachie S; Tanganuchitcharnchai A; Althaus T; Watthanaworawit W; Paris DH; Mayxay M; Peto TJ; Dondorp AM; White NJ; Day NP; Nosten F; Newton PN; Turner P
BMC Infect Dis; 2015 Nov; 15():511. PubMed ID: 26558692
[TBL] [Abstract][Full Text] [Related]
13. Myxovirus Resistance Protein A as a Marker of Viral Cause of Illness in Children Hospitalized with an Acute Infection.
Piri R; Yahya M; Ivaska L; Toivonen L; Lempainen J; Nuolivirta K; Tripathi L; Waris M; Peltola V
Microbiol Spectr; 2022 Feb; 10(1):e0203121. PubMed ID: 35080443
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic Accuracy of a Bacterial and Viral Biomarker Point-of-Care Test in the Outpatient Setting.
Shapiro NI; Filbin MR; Hou PC; Kurz MC; Han JH; Aufderheide TP; Ward MA; Pulia MS; Birkhahn RH; Diaz JL; Hughes TL; Harsch MR; Bell A; Suarez-Cuervo C; Sambursky R
JAMA Netw Open; 2022 Oct; 5(10):e2234588. PubMed ID: 36255727
[TBL] [Abstract][Full Text] [Related]
15. Combination of biomarkers for the discrimination between bacterial and viral lower respiratory tract infections.
ten Oever J; Tromp M; Bleeker-Rovers CP; Joosten LA; Netea MG; Pickkers P; van de Veerdonk FL
J Infect; 2012 Dec; 65(6):490-5. PubMed ID: 22898387
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of a combined MxA and CRP point-of-care immunoassay to identify viral and/or bacterial immune response in patients with acute febrile respiratory infection.
Sambursky R; Shapiro N
Eur Clin Respir J; 2015; 2():28245. PubMed ID: 26672961
[TBL] [Abstract][Full Text] [Related]
17. Economic Evaluation of FebriDx®: A Novel Rapid, Point-of-Care Test for Differentiation of Viral versus Bacterial Acute Respiratory Infection in the United States.
Dick K; Schneider J
J Health Econ Outcomes Res; 2021; 8(2):56-62. PubMed ID: 34703832
[No Abstract] [Full Text] [Related]
18. Outpatient Antibiotic Stewardship: A Growing Frontier-Combining Myxovirus Resistance Protein A With Other Biomarkers to Improve Antibiotic Use.
Joseph P; Godofsky E
Open Forum Infect Dis; 2018 Feb; 5(2):ofy024. PubMed ID: 29479553
[TBL] [Abstract][Full Text] [Related]
19. Negative predictive value of the FebriDx host response point-of-care test in patients presenting to a single Australian emergency department with suspected COVID-19: an observational diagnostic accuracy study.
Buntine P; Miller J; Pope A; Guy S; Wong FQA; McDonald H; Ahmed M; Teow KH; Roney M; Mohammadi F; Aldridge E; Hackett L; Jenner S; Davis B
BMJ Open; 2022 Dec; 12(12):e065568. PubMed ID: 36581427
[TBL] [Abstract][Full Text] [Related]
20. Use of the FebriDx point-of-care test for the exclusion of SARS-CoV-2 diagnosis in a population with acute respiratory infection during the second (COVID-19) wave in Italy.
Lagi F; Trevisan S; Piccica M; Graziani L; Basile G; Mencarini J; Borchi B; Menicacci L; Vaudo M; Scotti V; Fabbri A; Bandini G; Tozzetti C; Berni A; Aiezza N; Pestelli G; Turchi V; Pignone AM; Poggesi L; Nozzoli C; Morettini A; Rossolini GM; Bartoloni A
Int J Infect Dis; 2021 Jul; 108():231-236. PubMed ID: 33901656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
